At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ...

While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent. There are disparities in the ...

New data show precision cancer testing still lags for Black, Hispanic, low-income and Medicare/Medicaid patients, delaying ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for ...

Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center Of the 582 surveys sent, ...

NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor The Prostate Cancer Precision Medicine Multi ...

Next-generation sequencing (NGS) allows the simultaneous analysis of multiple genomic alterations with therapeutic implications, paving the way for precision medicine and transforming cancer care.

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...

Automating NGS sample preparation to accelerate microbiome research Microbiome research often involves complex workflows and ...

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...